|
Aurora Biomed
Our products and service are preferred by pharmaceutical and biotech companies for primary and secondary screening of ion channel drug targets. Compounds affecting these targets are widely believed to be among the next generation of blockbuster drugs. Our products are widely recognized as the fastest high-throughput approach for assessing a compound’s risk for QT interval prolongation.
The Ion Channel Reader (ICR) series combines the sensitivity of elemental analysis by atomic absorption spectroscopy with the simplicity of cell-based flux assays. In addition, Aurora has the ability to provide method development and custom systems for unique analysis needs
Contact information:
|
